LLY has delivered impressive returns of 15% year-to-date, outperforming the S&P 500’s 5% decline during the same period. This ...

Apollo chief economist Torsten Sløk predicted “empty shelves” in the next few weeks as a result of tariff-induced supply ...

An examination of recent litigation under the Employee Retirement Income Security Act of 1974 (ERISA) challenging allegedly ...

Haleon on Thursday raised its medium-term target for profit growth from 2026, banking on strength in key markets and costs ...

The U.S. Coast Guard offloaded $12.3 million worth of seized cocaine and marijuana in Florida after two interdictions in the ...

An FDA-designated orphan drug that can target a key vulnerability in lung cancer shows promise in improving the efficacy of ...

CVS Health sees strong Q1 2025 growth, but risks loom with downgraded revenue guidance and Medicare challenges. Read my ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

Look out for the key nutrients. When in doubt, try to prioritize foods with fiber and complex carbs, protein, and healthy ...

Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS ...

There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...